Search

Pacira Pharmaceuticals Inc-DE

Затворен

СекторЗдравеопазване

22.88 -0.65

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.77

Максимум

23.07

Ключови измерители

By Trading Economics

Приходи

1.7M

4.7M

Продажби

15M

192M

P/E

Средно за сектора

71.853

57.002

EPS

0.44

Марж на печалбата

2.418

Служители

825

EBITDA

-3.9M

26M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+29.35% upside

Дивиденти

By Acuity

Следващи печалби

5.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-85M

974M

Предишно отваряне

23.53

Предишно затваряне

22.88

Настроения в новините

By Acuity

34%

66%

86 / 340 Класиране в Healthcare

Pacira Pharmaceuticals Inc-DE Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 19:36 ч. UTC

Pacira Biosciences Inc shares are lower, marking the seventh consecutive decline. Broader market sentiment is affected by a reported drop in retail sales for July.

13.08.2026 г., 20:06 ч. UTC

Pacira Biosciences Inc shares fell during Thursday's session, continuing a trend of declines and remaining below the 20-day moving average. No specific news was identified.

12.08.2026 г., 20:01 ч. UTC

Pacira Biosciences Inc's shares are lower today, continuing a downward trend with a cumulative return of -3.36% since Tuesday. No specific news was identified.

11.08.2026 г., 19:16 ч. UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a trend of three consecutive declines. The stock is trading below its 20-day moving average.

10.08.2026 г., 19:36 ч. UTC

Pacira Biosciences Inc is trading lower, continuing a decline since Friday. The stock remains below its 20-day moving average amid broader market volatility.

7.08.2026 г., 20:02 ч. UTC

Event

Pacira Biosciences shares are lower despite positive two-year Phase 1 trial results for PCRX-201, an investigational gene therapy for knee osteoarthritis.

6.08.2026 г., 19:52 ч. UTC

News
Event

Pacira Biosciences Inc. shares are higher following positive two-year results from its Phase 1 trial for PCRX-201, a gene therapy for knee osteoarthritis.

5.08.2026 г., 20:03 ч. UTC

News

Pacira Biosciences reported improved earnings but lowered its 2026 revenue guidance, contributing to a decline in shares since Tuesday's close.

4.08.2026 г., 19:53 ч. UTC

Pacira Biosciences Inc is higher today, supported by overall market strength and a decline in crude oil prices easing inflation concerns.

3.08.2026 г., 20:06 ч. UTC

Pacira Biosciences Inc. shares are higher today, reflecting broader market gains led by major stocks, despite no specific company news identified.

31.07.2026 г., 20:02 ч. UTC

Pacira Biosciences Inc's shares are lower today, reaching a session low earlier. The price remains above its 20-day moving average despite the decline.

30.07.2026 г., 17:16 ч. UTC

Pacira Biosciences is advancing during Thursday's session, regaining momentum after earlier pulling back from a session high amid broader market optimism.

29.07.2026 г., 20:04 ч. UTC

Shares of Pacira Biosciences Inc. are lower today, continuing a decline since Tuesday's close. The stock reached an early high before falling significantly.

28.07.2026 г., 19:56 ч. UTC

Event
News

Shares of Pacira Biosciences Inc. are higher, driven by survey findings on orthopedic pain's impact on the workforce and strong interest in non-opioid treatments.

27.07.2026 г., 18:51 ч. UTC

Event
News

Pacira Biosciences advances PCRX-201 to commercial manufacturing, allowing patient enrollment in Phase 2 ASCEND study. Shares are higher as investor confidence strengthens.

24.07.2026 г., 17:16 ч. UTC

Pacira Biosciences Inc shares are lower today, with no specific news driving the decline. Broader market sentiment is impacted by falling crude oil prices.

22.07.2026 г., 18:06 ч. UTC

Pacira Biosciences Inc shares are lower in Wednesday's session, pulling back from earlier gains amid broader market caution and rising crude oil prices.

21.07.2026 г., 19:56 ч. UTC

Pacira Biosciences Inc is trading higher, reflecting broader market interest in technology and AI sectors ahead of upcoming earnings reports.

20.07.2026 г., 19:46 ч. UTC

Pacira Biosciences Inc shares are trading lower today, having retraced from an earlier high. No specific news was identified to explain the decline.

Сравнение с други в отрасъла

Ценова промяна

Pacira Pharmaceuticals Inc-DE Прогноза

Ценова цел

By TipRanks

29.35% нагоре

12-месечна прогноза

Среден 29.75 USD  29.35%

Висок 38 USD

Нисък 23 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pacira Pharmaceuticals Inc-DE през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

2

Купи

1

Задържане

1

Продай

Настроение

By Acuity

86 / 340 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
help-icon Live chat